DK0788356T3 - Fremgangsmåde og præparater til hæmning af proteinkinaser - Google Patents

Fremgangsmåde og præparater til hæmning af proteinkinaser

Info

Publication number
DK0788356T3
DK0788356T3 DK95941340T DK95941340T DK0788356T3 DK 0788356 T3 DK0788356 T3 DK 0788356T3 DK 95941340 T DK95941340 T DK 95941340T DK 95941340 T DK95941340 T DK 95941340T DK 0788356 T3 DK0788356 T3 DK 0788356T3
Authority
DK
Denmark
Prior art keywords
preparations
inhibition
methods
independently represents
protein kinases
Prior art date
Application number
DK95941340T
Other languages
English (en)
Inventor
Neill A Giese
Nathalie Lokker
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Application granted granted Critical
Publication of DK0788356T3 publication Critical patent/DK0788356T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DK95941340T 1994-10-28 1995-10-26 Fremgangsmåde og præparater til hæmning af proteinkinaser DK0788356T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/332,597 US5795910A (en) 1994-10-28 1994-10-28 Method and compositions for inhibiting protein kinases
PCT/US1995/013882 WO1996013259A2 (en) 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
DK0788356T3 true DK0788356T3 (da) 2002-03-18

Family

ID=23298937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95941340T DK0788356T3 (da) 1994-10-28 1995-10-26 Fremgangsmåde og præparater til hæmning af proteinkinaser

Country Status (14)

Country Link
US (3) US5795910A (da)
EP (1) EP0788356B9 (da)
JP (1) JPH10508024A (da)
KR (1) KR970706812A (da)
CN (1) CN1165481A (da)
AT (1) ATE210439T1 (da)
AU (1) AU706621B2 (da)
CA (1) CA2203757A1 (da)
DE (1) DE69524628T2 (da)
DK (1) DK0788356T3 (da)
ES (1) ES2170172T3 (da)
PT (1) PT788356E (da)
TW (1) TW467743B (da)
WO (1) WO1996013259A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
CN1146747C (zh) * 1996-08-06 2004-04-21 精工爱普生株式会社 液晶显示装置和使用液晶显示装置的电子仪器
AU5675099A (en) * 1998-08-17 2000-03-06 William E. Trout Use of zeranol to modulate reproductive cycles
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
BR9916879A (pt) * 1998-12-07 2001-11-06 Ecosmart Technologies Inc Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais
US6635671B1 (en) 1998-12-24 2003-10-21 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
WO2001012210A1 (en) * 1999-08-13 2001-02-22 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US6565864B2 (en) 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
CN100456962C (zh) * 2001-02-09 2009-02-04 荷兰联合利华有限公司 含大豆蛋白和抑制素的食物制品
US7553979B2 (en) * 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
FR2835252B1 (fr) 2002-01-25 2005-08-05 Seppic Sa Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
ES2555307T3 (es) * 2002-03-08 2015-12-30 Eisai R&D Management Co., Ltd. Compuestos macrocíclicos útiles como agentes farmacéuticos
US7915306B2 (en) * 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
WO2003086334A1 (fr) * 2002-04-17 2003-10-23 Taisho Pharmaceutical Co., Ltd. Produit tonique pour la pousse de cheveux
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
ES2388138T3 (es) 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
EP1794137A4 (en) 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
JP2009521493A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
CN103539769B (zh) * 2006-08-11 2016-03-16 斯特拉斯堡大学 用作激酶抑制剂和hsp90抑制剂的大环化合物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101778627B (zh) * 2007-07-25 2016-04-13 卫材R&D管理株式会社 用于治疗癌症的多激酶抑制剂
JP5564431B2 (ja) 2007-10-29 2014-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼアラレノンアナログ化合物ががんを処置する能力を予測する方法
EP2231634B1 (en) 2007-12-07 2016-05-11 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101928700B (zh) * 2009-07-28 2012-05-02 北京恒宇视野生物科技有限公司 蛋白激酶pftk1单克隆抗体及其制备方法
WO2012021974A1 (en) * 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10434085B2 (en) 2015-06-04 2019-10-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
JPS6239558A (ja) * 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−シアノアクリル酸アミド誘導体
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242923A (ja) * 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242925A (ja) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
GB9225396D0 (en) * 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
DE69524628T2 (de) 2002-08-08
WO1996013259A3 (en) 1996-08-01
CA2203757A1 (en) 1996-05-09
ATE210439T1 (de) 2001-12-15
AU706621B2 (en) 1999-06-17
US5795910A (en) 1998-08-18
MX9703113A (es) 1998-06-30
AU4278996A (en) 1996-05-23
DE69524628D1 (de) 2002-01-24
JPH10508024A (ja) 1998-08-04
CN1165481A (zh) 1997-11-19
WO1996013259A2 (en) 1996-05-09
ES2170172T3 (es) 2002-08-01
EP0788356A2 (en) 1997-08-13
TW467743B (en) 2001-12-11
PT788356E (pt) 2002-06-28
EP0788356B9 (en) 2002-10-02
US5728726A (en) 1998-03-17
KR970706812A (ko) 1997-12-01
EP0788356B1 (en) 2001-12-12
US5674892A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
DK0788356T3 (da) Fremgangsmåde og præparater til hæmning af proteinkinaser
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
EP0618221A3 (en) Heterocyclic farnesyl-protein transferase inhibitors.
YU31392A (sh) Derivati heterocikličnih-cikličnih amina
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
DE69516866T2 (de) Stereochemische wortmanninderivate
FI950859A (fi) Arylideeni- ja heteroarylideeni-oksindolijohdannaiset tyrosiinikinaasi-inhibiittoreina
NO961814D0 (no) Substituerte di- og tripetidinhibitorer for protein:farnesyl-transferase
NO983892L (no) Inhibitorer for farnesyl-proteintransferase
DE69627179D1 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
NZ506771A (en) Modified factor viii
NO991230D0 (no) Trisykliske forbindelser for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
DE69225023T2 (de) Amin-Addukte als Korrosionsinhibitoren
DE69416518T2 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
PL330786A1 (en) Inhibitors of prenyl transferase
DK261482A (da) Maettede aminocyclitolderivater og fremgangsmaade til deres fremstilling
ATE262584T1 (de) Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40
DK0950056T3 (da) N-(pyridinylamino)isoindoliner og beslægtede forbindelser
NO970350L (no) Forbindelser anvendelige som anti-formeringsmidler og GARFT-inhibitorer
AR003529A1 (es) Derivados de alfa-fenilpiperidin-1-propanol, procedimiento para su preparacion y su aplicacion terapeutica.
ATE227281T1 (de) Verbindungen als farnesyl-protein transferase inhibitoren